Yes, it is counterintuitive. This article https:/
Post# of 153834
(Total Views: 531)
Posted On: 02/17/2020 10:03:47 AM
Yes, it is counterintuitive. This article https://www.frontiersin.org/articles/10.3389/...81/full#h4
is a very interesting examination of not only Antibody Dependent Enhanced (ADE) infection resulting from Non-Neutralizing Antibodies (NNAs) but also the difficulties that may be ahead with the development of a vaccine for 2019-nCoV.
In the case of MERS, ADE infections have not been seen yet. On the other hand, ADE infections have been noted with SARS. The fact that plasma infusions are apparently efficacious as misiu143 notes, is a good sign.
Point is, we just don't know yet how this coronavirus will behave in so many ways.
We can certainly hope that antivirals such as Remdesivir, lopinavir/ritonavir will be effective. It is also reasonable that leronlimab might be useful as a therapeutic in throttling lung damage from an overactive immune system. However, what we see, is that even in a given virus family, behavior to antivirals and therapeutics is highly variable. So, we can only hope at this point.
is a very interesting examination of not only Antibody Dependent Enhanced (ADE) infection resulting from Non-Neutralizing Antibodies (NNAs) but also the difficulties that may be ahead with the development of a vaccine for 2019-nCoV.
In the case of MERS, ADE infections have not been seen yet. On the other hand, ADE infections have been noted with SARS. The fact that plasma infusions are apparently efficacious as misiu143 notes, is a good sign.
Point is, we just don't know yet how this coronavirus will behave in so many ways.
We can certainly hope that antivirals such as Remdesivir, lopinavir/ritonavir will be effective. It is also reasonable that leronlimab might be useful as a therapeutic in throttling lung damage from an overactive immune system. However, what we see, is that even in a given virus family, behavior to antivirals and therapeutics is highly variable. So, we can only hope at this point.
(1)
(0)